Found 20231 Enz. Inhib. hit(s) with all data for entry = 50048085 
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetHepatocyte growth factor receptor [1-13,15-1390](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen™ Eu Kinase Binding technol...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
